Tesamorelin (Egrifta): Evidence and Safety
Tesamorelin is a growth-hormone-releasing hormone (GHRH) analog that is FDA-approved, as Egrifta, specifically for reducing excess abdominal fat in adults with HIV-associated lipodystrophy. Using it for general fat loss, muscle gain, or anti-aging in people without that condition is off-label and not what its approval is based on, despite the “GH secretagogue for longevity” framing it gets in biohacker circles.
Understand the mechanism A GHRH analog: it stimulates the body's own pituitary gland to release growth hormone, rather than supplying growth hormone directly.
This indirect mechanism is why tesamorelin is discussed alongside other GH-axis peptides, though its approval is narrow.
See what the approval actually covers FDA-approved in 2010 (Egrifta) for reduction of excess abdominal fat in adults with HIV-associated lipodystrophy; reformulated as Egrifta SV (2019) and Egrifta WR (approved March 25, 2025) for the same indication.
The evidence tracks the approved indication, not the broader “GH secretagogue for longevity” use it gets marketed for.
Know what is and is not approved FDA-approved, but only for HIV-associated lipodystrophy. Using tesamorelin for general fat loss, muscle gain, or anti-aging in people without that condition is off-label.
The approval is condition-specific; it is not a general-use GH-axis approval.
Know the labeled risks Labeled risks include injection-site reactions, joint pain, and a theoretical concern around GH-axis stimulation (glucose intolerance); the label carries caution around malignancy given GH's growth-promoting mechanism, standard for GH-axis drugs. Off-label or compounded “tesamorelin” for cosmetic or longevity use bypasses this safety monitoring.
These are the labeled risks for the approved population; off-label use in a different population has not been evaluated the same way.
The FDA first approved tesamorelin in 2010 (as Egrifta) specifically for reduction of excess abdominal fat in adults with HIV-associated lipodystrophy; it was reformulated as Egrifta SV in 2019, and a further reformulation, Egrifta WR, received FDA approval on March 25, 2025 for the same indication with a simpler weekly-reconstitution regimen.
View sources
Huberman Lab: Benefits & Risks of Peptide Therapeutics for Physical & Mental Health (confirms tesamorelin's FDA approval for HIV-associated lipodystrophy)
Not medical advice. This page is for education only and is not a substitute for professional medical care. Consult a qualified clinician before changing your health routine.
Editorial disclosure. This protocol is written and fact-checked by the YourProtocol editorial team directly from the primary sources cited below; it is not written or reviewed by any outside expert.
Is this for you
- Anyone trying to understand what tesamorelin or Egrifta is actually approved for
- Anyone who has seen tesamorelin marketed for general fat loss or anti-aging and wants the approved-use boundary
- Patients or caregivers preparing questions for a prescriber
- Readers comparing tesamorelin to unregulated GH-secretagogue “research peptides”
Cautions
- Educational only, not medical advice; any decision about a prescription medication belongs with a licensed prescriber.
- The FDA approval covers HIV-associated lipodystrophy specifically, not general fat loss, muscle gain, or anti-aging.
- The label carries a malignancy caution standard for GH-axis drugs; discuss personal risk factors with a prescriber.